The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK).
G. J. Fetterly
No relevant relationships to disclose
K. E. Thudium
No relevant relationships to disclose
J. Kalabus
No relevant relationships to disclose
M. Murphy
No relevant relationships to disclose
P. D. Zagst
No relevant relationships to disclose
J. Prey
No relevant relationships to disclose
E. Kittleman
No relevant relationships to disclose
A. A. Adjei
No relevant relationships to disclose
T. L. O'Connor
No relevant relationships to disclose
J. G. Blanco
No relevant relationships to disclose